Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease

NCT00589797 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2018-12-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn whether an investigational device called the Activ-L Artificial Disc is safe and effective in the treatment of degenerative disc disease of the lower (lumbar) spine.

Conditions

  • Degenerative Disc Disease

Interventions

DEVICE

Activ-L Artificial Disc

Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.

DEVICE

ProDisc-L Total Disc Replacement or Charité Artificial Disc

Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.

Sponsors & Collaborators

  • Aesculap Implant Systems

    lead INDUSTRY

Principal Investigators

  • Rolando Garcia, M.D. · Orthopedic Care Center

  • James J Yue, M.D. · Yale University

  • Dom Coric, M.D. · Carolina Neurosurgery and Spine Associates

  • Steven Dennis, M.D. · Hoag Memorial Hospital Presbyterian

  • Federico P. Girardi, M.D. · Hospital for Special Surgery, New York

  • Mick Perez-Cruet, M.D. · Michigan Head and Spine Institute

  • Harel Deutsch, M.D. · Rush University Medical Center

  • Glenn Buttermann, M.D. · Midwest Spine Institute

  • Dzung Dinh, M.D. · Neuroscience Education and Research Foundation

  • Vikas Patel, M.D. · University of Colorado, Denver

  • Christopher Ames, M.D. · University of California, San Francisco

  • John Regan, M.D. · St. John's Hospital and Health Center

  • Andrew Dailey, M.D. · University of Utah Medical Center

  • Darren Bergey, M.D. · Rancho Specialty Hospital

  • Brian Dalton, M.D. · Hamot Medical Center

  • Scott Leary, M.D. · Scripps Memorial Hospital La Jolla

  • David Hart, M.D. · University Hospitals Cleveland

  • Antonio Castellvi, M.D. · Foundatin for Orthopaedic Research and Education

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2012-12-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00589797 on ClinicalTrials.gov